標(biāo)題: Titlebook: Immunotherapy for Pediatric Malignancies; Juliet C. Gray,Aurélien Marabelle Book 2018 Springer International Publishing Switzerland 2018 A [打印本頁(yè)] 作者: NO610 時(shí)間: 2025-3-21 19:51
書(shū)目名稱Immunotherapy for Pediatric Malignancies影響因子(影響力)
書(shū)目名稱Immunotherapy for Pediatric Malignancies影響因子(影響力)學(xué)科排名
書(shū)目名稱Immunotherapy for Pediatric Malignancies網(wǎng)絡(luò)公開(kāi)度
書(shū)目名稱Immunotherapy for Pediatric Malignancies網(wǎng)絡(luò)公開(kāi)度學(xué)科排名
書(shū)目名稱Immunotherapy for Pediatric Malignancies被引頻次
書(shū)目名稱Immunotherapy for Pediatric Malignancies被引頻次學(xué)科排名
書(shū)目名稱Immunotherapy for Pediatric Malignancies年度引用
書(shū)目名稱Immunotherapy for Pediatric Malignancies年度引用學(xué)科排名
書(shū)目名稱Immunotherapy for Pediatric Malignancies讀者反饋
書(shū)目名稱Immunotherapy for Pediatric Malignancies讀者反饋學(xué)科排名
作者: 新手 時(shí)間: 2025-3-21 21:43
Overcoming Immune Suppression in the Tumor Microenvironment: Implications for Multi-modal Therapy,h of which release a wave of tumor antigens. The choice of whether to treat these antigens as tolerizing or immunizing is fundamental to generating an effective immune response against the tumor. In this chapter we consider immunosuppressive mechanisms in the tumor microenvironment from the perspect作者: ADAGE 時(shí)間: 2025-3-22 02:24 作者: Prostaglandins 時(shí)間: 2025-3-22 06:56 作者: Terrace 時(shí)間: 2025-3-22 12:01 作者: 神圣在玷污 時(shí)間: 2025-3-22 16:30 作者: 巨碩 時(shí)間: 2025-3-22 17:32 作者: 繁忙 時(shí)間: 2025-3-23 00:03 作者: 華而不實(shí) 時(shí)間: 2025-3-23 02:37 作者: flimsy 時(shí)間: 2025-3-23 05:38
Juliet C. Gray M.A., FRCPCH, Ph.D.,Paul M. Sondel M.D., Ph.D.ion with disease duration. Patients with cerebellar degeneration showed lower resting MSNA than the healthy controls, while there were no significant differences of age, resting HR, or resting BP between the patients and healthy controls. In patients with cervical spondylosis, the resting MSNA was p作者: 方舟 時(shí)間: 2025-3-23 10:52
Matthew J. Barth M.D.,Jessica Hochberg M.D.,Nader Kim El-Mallawany M.D.,Mitchell S. Cairo M.D.ich regulates mainly sweat glands and skin blood vessels plays important roles in thermoregulation. Recordings of MSNA and SSNA have been widely applied to analyze sympathetic mechanisms in various disease conditions, as well as stressful situations when the human body is exposed to various environm作者: Kidney-Failure 時(shí)間: 2025-3-23 17:44 作者: 錫箔紙 時(shí)間: 2025-3-23 18:09 作者: 信條 時(shí)間: 2025-3-24 02:15
Aurelien Marabelle M.D., Ph.D.,Juliet C. Gray M.A., FRCPCH, Ph.D.s with two dedicated chapters covering bone SPECT/CT imaging in sports injuries and oncology. Featuring many high-quality illustrations,?.Clinical Atlas of Bone SPECT/CT.?.will be an invaluable resource for all nuclear medicine physicians.. .It is published as part of the SpringerReference program, 作者: immunity 時(shí)間: 2025-3-24 04:45
adiotherapy..Edited by two distinguished pediatric oncologists with a collection of chapters from the most authoritative experts in cancer immunotherapy, this is an indispensable volume for pediatric oncologists and physicians working in childhood cancer care.. .978-3-319-82837-4978-3-319-43486-5作者: 嘴唇可修剪 時(shí)間: 2025-3-24 07:52
in Criteria, should influence the clinical assessment of children and adolescents..Provides updates to professional standards that should guide test users..Discusses practical considerations in planning and con978-3-030-35697-2978-3-030-35695-8作者: 高度贊揚(yáng) 時(shí)間: 2025-3-24 11:47
Miho Nakajima M.D.,Shakeel Modak M.D., M.R.C.P.gy. Featuring many high-quality illustrations,?.Clinical Atlas of Bone SPECT/CT.?.will be an invaluable resource for all nuclear medicine physicians.. .It is published as part of the SpringerReference program, 978-3-031-26449-8作者: JEER 時(shí)間: 2025-3-24 16:27
Michaela Semeraro,Claudia Pasqualini,Nathalie Chaputgy. Featuring many high-quality illustrations,?.Clinical Atlas of Bone SPECT/CT.?.will be an invaluable resource for all nuclear medicine physicians.. .It is published as part of the SpringerReference program, 978-3-031-26449-8作者: sclera 時(shí)間: 2025-3-24 19:45 作者: Aerate 時(shí)間: 2025-3-25 00:50 作者: 6Applepolish 時(shí)間: 2025-3-25 03:25 作者: 量被毀壞 時(shí)間: 2025-3-25 07:38
Immune Adjuvants and Cytokine Therapies,re molecules released by different cell types in the extracellular milieu that play essential roles in intercellular communication. Cytokines represent a category of IA, and will be discussed here in detail, as they have already achieved widespread use in pediatric oncology.作者: 魔鬼在游行 時(shí)間: 2025-3-25 12:30
ncies.Addresses key issues, such as immune-related toxicitie.This book provides a comprehensive overview of current immunotherapy strategies, and how these may be applicable to childhood cancers. The first part of the book reviews how the immune system recognizes cancer, and the various escape mecha作者: 卡死偷電 時(shí)間: 2025-3-25 16:07
Monoclonal Antibodies Directly Targeting Antigens on Solid Tumours, dramatically increasing over the years. Although approval rates in paediatric indications stay far behind, the clinical utility of Mabs in paediatric oncology is clearly acknowledged and will be discussed in the following chapters with focus on neuroblastoma.作者: 凝結(jié)劑 時(shí)間: 2025-3-25 20:07
Book 2018 of the book reviews how the immune system recognizes cancer, and the various escape mechanisms allowing tumour growth. The importance of the tumor microenvironment and the challenges this may present to achieving effective immunotherapy are discussed. Monoclonal antibodies, cellular, cytokine and v作者: macular-edema 時(shí)間: 2025-3-26 02:59 作者: harrow 時(shí)間: 2025-3-26 06:36 作者: DEAWL 時(shí)間: 2025-3-26 10:49
NK Cell and NKT Cell Immunotherapy, of both the innate and adaptive immune system, and express an invariant T cell receptor (iNKT cells) that recognizes glycolipid antigens in the context of the MHC class-I-like CD1d molecule. iNKT cells are also being utilized for cancer immunotherapy.作者: deriver 時(shí)間: 2025-3-26 13:21 作者: ALIBI 時(shí)間: 2025-3-26 18:40
practical guidelines for implementing individual tests acros.The fourth edition of this textbook offers a scientific and practical context within which to understand and conduct clinical assessments of children’s and adolescent’s personality and behavior. The new edition ensures that the content is 作者: hardheaded 時(shí)間: 2025-3-26 21:42
Aurélien Marabelle M.D., Ph.D.,Claudia Rossig M.D.%) were related to ten diseases, which, in their natural course, cause suffering in all dimensions—physical, emotional, family, social, and spiritual—despite all available treatments. These diseases have remained the principal causes of global death for the last 15?years, and it is worth mentioning 作者: 祖先 時(shí)間: 2025-3-27 02:12
Theodore S. Johnson M.D.,David H. Munn M.D.%) were related to ten diseases, which, in their natural course, cause suffering in all dimensions—physical, emotional, family, social, and spiritual—despite all available treatments. These diseases have remained the principal causes of global death for the last 15?years, and it is worth mentioning 作者: 陳舊 時(shí)間: 2025-3-27 07:58
Patrick Schlegel M.D.,Christian Seitz M.D.,Peter Lang M.D.,Rupert Handgretinger M.D.ninvasively assess the pathophysiology of postganglionic cardiac sympathetic nerve endings. Cardiac scintigraphy using MIBG radiolabeled with iodine-123 (.I-MIBG) has been applied to patients with pheochromocytoma and various types of heart disease as well as neurological disorders, including Parkin作者: 受辱 時(shí)間: 2025-3-27 11:28 作者: mosque 時(shí)間: 2025-3-27 16:37
Matthew J. Barth M.D.,Jessica Hochberg M.D.,Nader Kim El-Mallawany M.D.,Mitchell S. Cairo M.D.the muscle and skin called muscle sympathetic nerve activity (MSNA) and skin sympathetic nerve activity (SSNA). In this chapter, the author explains (1) what is microneurography, (2) the recording technique of microneurography, (3) how to identify MSNA and SSNA, and (4) applications of sympathetic m作者: esoteric 時(shí)間: 2025-3-27 21:10 作者: Living-Will 時(shí)間: 2025-3-27 23:50 作者: indifferent 時(shí)間: 2025-3-28 04:02 作者: 符合規(guī)定 時(shí)間: 2025-3-28 08:56
Michaela Semeraro,Claudia Pasqualini,Nathalie Chaputfindings and common pitfalls and features richly illustrated.This clinical atlas is a comprehensive reference work on bone and joint disorders that can be characterized and assessed with hybrid bone SPECT/CT. It is structured according to the major joints and regions of the skeletal system, includin作者: 黑豹 時(shí)間: 2025-3-28 14:28 作者: 儲(chǔ)備 時(shí)間: 2025-3-28 16:42
Introduction to Pediatric Cancer Immunotherapy,points PD-1/PD-L1 and CTLA-4/B7 are providing durable responses and overall survival benefits in multiple relapsing/refractory adult cancer types. Novel immunotherapies such as oncolytic viruses and adoptive CAR-T cells are also becoming approved immune therapies and revolutionize the world of drug 作者: 條街道往前推 時(shí)間: 2025-3-28 19:25
Overcoming Immune Suppression in the Tumor Microenvironment: Implications for Multi-modal Therapy,immunosuppressive tumor microenvironment. This problem is more than just the suppression of effector T cells, but also includes profound defects in the inflammatory milieu and immunogenic antigen-presenting cells that are required to drive T cell activation. To date, much of the field of immunothera作者: Instantaneous 時(shí)間: 2025-3-29 01:33 作者: 小步走路 時(shí)間: 2025-3-29 07:07
Overview of Monoclonal Antibody Therapies,argeting almost any antigen of choice, opening the door to widespread application. Since the first monoclonal antibody was licensed for clinical use 30 years ago, there has been an exponential growth in our knowledge of how they may be used therapeutically, particularly in the treatment to cancer. T作者: 性上癮 時(shí)間: 2025-3-29 08:53 作者: sinoatrial-node 時(shí)間: 2025-3-29 13:38
Monoclonal Antibodies Directly Targeting Antigens on Solid Tumours,5 to clinical applicability and finally to approved drugs for cancer immunotherapy in the late 1990s. The number of approved Mabs in adult oncology is dramatically increasing over the years. Although approval rates in paediatric indications stay far behind, the clinical utility of Mabs in paediatric作者: 感染 時(shí)間: 2025-3-29 15:45
Monoclonal Antibodies Targeting the Immune System,f immune cancer evasion has enabled the development of new cancer immunotherapy targeted to inhibitory immune checkpoints: PD-1, PD-L1 and CTLA4. Dramatic results were obtained in advanced melanoma (34% survival at 5 years with anti-PD-1) and non-small cell lung cancer, and proof of efficacy has bee作者: 織布機(jī) 時(shí)間: 2025-3-29 21:13
,Adoptive T Cell Therapies for Children’s Cancers,cacy of T cells in paediatric cancer was seen in the “graft-versus-leukaemia” effects following allogeneic bone marrow transplantation. Subsequently, the approach has been trialled in solid tumours following genetic modification of T-cells to retarget them against cancer. Optimised T-cell products c作者: –吃 時(shí)間: 2025-3-30 03:05 作者: bifurcate 時(shí)間: 2025-3-30 04:59 作者: SCORE 時(shí)間: 2025-3-30 11:07 作者: 虛假 時(shí)間: 2025-3-30 16:02
Immune Biomarkers in Paediatric Malignancies,ents are rarely effective in all patients, predictive biomarkers to identify those most likely to benefit from a specific therapy are useful. Identification of biomarkers may also improve our understanding of how treatments work, as well as resistance mechanisms, and thus be used not only to anticip作者: inveigh 時(shí)間: 2025-3-30 16:46
Future Perspectives,tment of many tumour types, and changing the paradigm of treatment in oncology by targeting immune cells rather than cancer cells. Antagonistic antibodies blocking immunosuppressive pathways such as PD-1/PD-L1 have shown anti-tumor activity in patients with advanced relapsed and refractory cancers t
